GLUMETZA®—Designed to Help You Reach Your Treatment Goals
What can I expect from treating type 2 diabetes with GLUMETZA?
- GLUMETZA may help you in controlling your type 2 diabetes with fewer stomach-related side effects, such as nausea, in the first week of taking your medication.
- Fewer stomach-related side effects may enable you to continue your treatment and reach your treatment goals.
- GLUMETZA is taken just once a day, which may make it easier for you to remember.
- GLUMETZA is available in both 500 mg and 1000 mg tablets.
- The 1000 mg tablet is designed for greater convenience because it reduces the number of pills you need to take.
In clinical trials, the most common side effects with GLUMETZA monotherapy were diarrhea, nausea, dyspepsia, and upper abdominal pain. In a
clinical trial of GLUMETZA combined with a sulfonylurea, the most common side effects included hypoglycemia, diarrhea, and nausea.
Learn more about possible side effects of GLUMETZA.
What is the advanced technology of GLUMETZA?
Unlike immediate-release metformin, GLUMETZA uses advanced technology that delivers the type 2 diabetes medicine slowly and
steadily over several hours. This delay in the release of metformin may result in fewer stomach-related side effects, such as nausea, in
the first week of taking your medication.
Learn more about the advanced technology of GLUMETZA.
GLUMETZA is a biguanide indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Important Safety Information
GLUMETZA is contraindicated in patients with:
- Renal impairment (e.g., serum creatinine levels ≥ 1.5 mg/dL for men, ≥ 1.4 mg/dL for women or abnormal creatinine clearance), which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia (see WARNINGS and PRECAUTIONS (5) of the Full Prescribing Information).
- Known hypersensitivity to metformin hydrochloride.
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis. Diabetic ketoacidosis should be treated with insulin.
Hypoglycemia does not occur in patients receiving metformin alone under usual circumstances of use, but could occur when caloric intake is deficient, when strenuous exercise is not compensated by caloric supplementation, or during concomitant use with other glucose-lowering agents (such as sulfonylureas and insulin) or ethanol. Elderly, debilitated, or malnourished patients, and those with adrenal or pituitary insufficiency or alcohol intoxication are particularly susceptible to hypoglycemic effects. Hypoglycemia may be difficult to recognize in the elderly, and in people who are taking beta-adrenergic blocking drugs.
In clinical trials, the most common side effects with GLUMETZA monotherapy were diarrhea, nausea, dyspepsia, and upper abdominal pain. In clinical trials of GLUMETZA combined with a sulfonylurea, the most common side effects included hypoglycemia, diarrhea, and nausea.
Dosage and Administration
- Administer once daily with the evening meal.
- Individualize the dose based on effectiveness and tolerability, while not exceeding the maximum recommended daily dose of 2000 mg.
- If naïve to metformin treatment, initiate with 500 mg daily.
- Swallow whole. Never split, crush or chew.
Dosage Forms and Strengths
Extended Release Tablets, 500 mg and 1000 mg
For the Full Prescribing Information, including Black Box Warning, please click here. Please consult with your healthcare professional to see if GLUMETZA is right for you.
To report a Product Adverse Event or Product Complaint: 1-888-778-0887, Monday-Friday, 9:00 am-7:00 pm Eastern Time
Note: You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Adobe® Acrobat® Reader is required to view these documents. Download now.
The content of this website is not a substitute for professional medical advice and should not be interpreted as treatment recommendations or relied on for medical diagnosis or treatment. Please see complete Legal Disclaimer.
This site is intended for the exclusive use of residents of the United States of America.
Glumetza® and Smartcoat® are registered trademarks of Biovail Laboratories International S.r.l. AcuForm® is a registered trademark of Depomed. Inc.
Back to Top